» Articles » PMID: 16968352

Incidence and Risk Factors for Hepatitis C Seroconversion in Injecting Drug Users in Australia

Overview
Journal Addiction
Specialty Psychiatry
Date 2006 Sep 14
PMID 16968352
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine the incidence of hepatitis C virus (HCV) infection and identify risk factors for seroconversion.

Design: Prospective cohort study. Participants were recruited through direct approaches, street-based outreach, methadone and sexual health clinics and needle and syringe programmes.

Setting: Urban, regional and rural settings in New South Wales, Australia.

Participants: Injecting drug users (IDUs) (n = 584) were screened and tested for exposure to HCV. Between 1999 and 2002 antibody HCV negative IDUs (n = 368) were enrolled and followed-up every 3-6 months until seroconversion or study completion.

Measurements: Interviewer-administered baseline and follow-up questionnaires consisted of 131 items and included demographics, drug use and risk behaviour. Approximately 10 cc of whole blood was drawn at each visit. Specimens were stored at -70C and serology performed using one or two third-generation enzyme-linked immunosorbent assays and polymerase chain reaction testing.

Findings: Sixty-eight seroconversions were observed and incidence was 30.8 per 100 person-years, with incidence in IDUs injecting < 1 year, 133 per 100 person-years. Independent predictors of seroconversion were female gender, duration of injecting, injecting cocaine, shared use of filters and recruitment strategy.

Conclusions: Women, new initiates and IDUs recruited via outreach appear to be at increased risk of infection. Results confirm the significance of cocaine injection as a risk factor and provide the first evidence outside North America of the link between shared use of drug preparation equipment and incident HCV infection. Prevention efforts should attempt to raise awareness of the risks associated with drug sharing and, in particular, the role of potentially contaminated syringes in HCV infection.

Citing Articles

Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.

Shih S, Stone J, Martin N, Hajarizadeh B, Cunningham E, Kwon J Open Forum Infect Dis. 2024; 11(2):ofad637.

PMID: 38344130 PMC: 10854215. DOI: 10.1093/ofid/ofad637.


Context and correlates of providing assistance with someone's first injection in the AIDS linked to the IntraVenous Experience cohort, Baltimore, MD.

Gicquelais R, Astemborski J, Werb D, Kirk G, Mehta S, Genberg B Drug Alcohol Depend. 2023; 250:110909.

PMID: 37517262 PMC: 10529208. DOI: 10.1016/j.drugalcdep.2023.110909.


Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.

Aung P, Spelman T, Wilkinson A, Dietze P, Stoove M, Hellard M Epidemiol Infect. 2023; 151:e84.

PMID: 37157844 PMC: 10226186. DOI: 10.1017/S0950268823000675.


Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.

Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim A Lancet Gastroenterol Hepatol. 2023; 8(6):533-552.

PMID: 36996853 PMC: 10817215. DOI: 10.1016/S2468-1253(23)00018-3.


Acute hepatitis C virus infection: clinical update and remaining challenges.

Liu C, Kao J Clin Mol Hepatol. 2023; 29(3):623-642.

PMID: 36800699 PMC: 10366792. DOI: 10.3350/cmh.2022.0349.